|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/30 | |
| C07K 16/28 | |||
| A61P 35/00 |
| (11) | Number of the document | 3400246 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17700491.8 |
| Date of filing the European patent application | 2017-01-05 | |
| (97) | Date of publication of the European application | 2018-11-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-10-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2017/050168 |
| Date | 2017-01-05 |
| (87) | Number | WO 2017/118675 |
| Date | 2017-07-13 |
| (30) | Number | Date | Country code |
| 16150506 | 2016-01-08 | EP |
| (72) |
BACAC, Marina, CH
COLOMBETTI, Sara, CH
KLEIN, Christian, CH
SAM, Johannes, CH
SARO, Jose, CH
UMAŃA, Pablo, CH
|
| (73) |
F. Hoffmann-La Roche AG,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES |
| METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES |